Liquid APPA Formulation via Eutectic Mixture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory and analgesic formulations, particularly those combining 4-hydroxy-3-methoxyacetophenone (apocynin) and 2-hydroxy-4-methoxyacetophenone (paeonol), face challenges with transient melting and adverse transformation during granulation, leading to inferior bioavailability and compliance issues due to unpleasant taste and high dosing requirements, especially in neurodegenerative disease treatments.
Innovation Solution
A stable liquid formulation is achieved by forming a eutectic mixture of apocynin and paeonol with a low-toxicity excipient like polyethylene glycol 400, which significantly lowers the melting point and maintains a high concentration of active compounds, allowing for a concentrated, room-temperature stable solution that can be encapsulated in a single soft gel capsule.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If a solid dose form is used, then the formulation is stable during storage, but heat induced during granulation and compression causes transient melting of paeonol and adverse transformation of physical properties
Solution Approach 1:
The patent changes the physical state parameter of the formulation from solid to liquid. By formulating APPA as a liquid preparation, the invention avoids the heat-induced melting and transformation issues that occur during solid dose manufacturing processes like granulation and compression.
Solution Approach 2:
The patent utilizes phase transition by maintaining the formulation in the liquid phase rather than converting it to solid. This prevents the transient melting and subsequent adverse transformation of paeonol's physical properties that occurs when solid formulations are subjected to manufacturing heat.
2Ease of operation
If a solid phase preparation is used, then the formulation is easy to administer, but bioavailability is inferior to liquid preparations
Solution Approach 1:
The patent changes the dosage form parameter from solid to liquid to improve bioavailability. Liquid preparations are inherently more bioavailable than solid forms, and this invention maintains that advantage while addressing administration convenience through encapsulation or other delivery mechanisms.
3Ease of operation
If the active ingredients are dissolved or suspended in liquid, then the formulation is easy to administer, but the concentration of active ingredients is reduced
Solution Approach 1:
The patent changes the formulation state to liquid while maintaining high concentration of active ingredients. Unlike conventional liquid preparations that require large volumes and have low concentration, this invention achieves both high concentration (64.3% w/w) and liquid state, allowing easy administration with small volumes.
4Ease of operation
If a standardised liquid extract is used, then the formulation can be orally ingested, but the volume required is large and tastes unpleasant
Solution Approach 1:
The patent changes the concentration parameter dramatically, achieving 64.3% w/w active ingredient concentration in liquid form. This high concentration reduces the required volume from large amounts of conventional liquid extracts to small, palatable volumes that are easy to administer.
5Quantity of substance
If multiple capsules or large volumes of liquid are required, then the dosage can be sufficient, but patient compliance decreases
Solution Approach 1:
The patent changes the concentration parameter to achieve high potency in a single capsule. By formulating with 64.3% w/w APPA concentration, the invention allows sufficient therapeutic dosage to be delivered in one capsule rather than multiple capsules or large liquid volumes, thereby improving patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides a highly concentrated, stable, and palatable liquid form of APPA, improving patient compliance and dosing convenience, especially for clinically vulnerable groups, by maintaining a high concentration of active ingredients and avoiding the need for multiple capsules or large volumes of liquid.
Implementation Method 1
the applicants have surprisingly found that at (or close to) this ratio a eutectic mixture is formed resulting in a significantly lowered combined melting point of 44.7° C.; below that of both paeonol and apocynin
Implementation Method 2
addition of a relatively small quantity of an excipient to the eutectic APPA mixture provides a liquid form of APPA which is stable at room temperature
Data Source
AI summary
A stable liquid formulation is provided. The liquid formulation includes a composition of active ingredients paeonol and apocynin. Methods of production of such a formation and treatment of diseases administering such a formulation are also provided.